Satralizumab

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

Chugai Pharmaceutical Co. released data showing Enspryng had a favorable benefit-risk profile and effectively reduced relapses over 4 years of treatment among people with a form of neuromyelitis optica spectrum disorder.

The European Commission has approved Enspryng for treatment of adults and adolescents with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Roche press release.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Enspryng to be approved to treat neuromyelitis optica spectrum disorder in people aged 12 years and older, according to a Roche press release.

In the last year, three therapies were approved by the FDA to significantly reduce relapses of neuromyelitis optica spectrum disorder, a rare autoimmune inflammatory disorder that can leave patients blind or paralyzed.

Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting.

The FDA has approved Enspryng for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Genentech press release.

Japan’s Ministry of Health, Labour and Welfare approved Enspryng to treat adults and children with neuromyelitis optica spectrum disorder, according to a press release.